Join
Live feed
·
PRReleasevia Quantisnow
Acurx Pharmaceuticals Inc. logo

Acurx Pharmaceuticals Announces First Patient Enrolled in PATHFINDER Clinical Trial of Ibezapolstat in Multiply-Recurrent C. difficile Infection

ByQuantisnow·Wall Street's wire, on your screen.
ACXP· Acurx Pharmaceuticals Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ACXP (Acurx Pharmaceuticals Inc.) and more on Quantisnow.